Ocuphire Pharma Inc
NASDAQ:OCUP
Ocuphire Pharma Inc
Total Equity
Ocuphire Pharma Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocuphire Pharma Inc
NASDAQ:OCUP
|
Total Equity
$40.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
24%
|
CAGR 10-Years
3%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$92.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$51.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$23.8B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
5%
|
|
Ocuphire Pharma Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.
See Also
What is Ocuphire Pharma Inc's Total Equity?
Total Equity
40.6m
USD
Based on the financial report for Jun 30, 2024, Ocuphire Pharma Inc's Total Equity amounts to 40.6m USD.
What is Ocuphire Pharma Inc's Total Equity growth rate?
Total Equity CAGR 10Y
3%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Ocuphire Pharma Inc have been 22% over the past three years , 24% over the past five years , and 3% over the past ten years .
